BackZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Overview

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Total Assets

Track ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s total assets ($740M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$742.22M
96.46% YoYΔ $-20.24B vs prior year quarter

Peer average

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Total Assets History

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) vs. peers: Total Assets Comparison

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) (LSPRU) FAQ

The latest total assets for LSPRU is $740M as of March 2026. That compares with $21B in the prior-year period — down 96.5% year over year. Investors often review this figure alongside ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, LSPRU's total assets moved from $21B to $740M — a 96.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s operating scale or balance-sheet position.

A total assets figure of $740M for LSPRU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LSPRU's total assets ($740M), review year-over-year change from $21B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.